IDEXX Laboratories Slashes FY22 Outlook - Update

While reporting financial results for the second quarter on Tuesday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) slashed its earnings and revenue growth guidance for the full-year 2022.

For fiscal 2022, the company now projects earnings in a range of $7.77 to $8.05 per share on revenues between $3.305 billion and $3.385 billion, with revenue growth of 3 to 5.5 percent and organic revenue growth of 5.5 to 8 percent.

Previously, the company expected earnings in a range of $8.11 to $8.35 per share on revenue growth of 5.5 to 8 percent and organic revenue growth of 7.5 to 10 percent.

On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $8.27 per share on revenues of $3.42 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retailers Dollar General Corp. (DG) and Big Lots, Inc. (BIG) reported Thursday results for the third quarter, with profit at Dollar General increasing from last year, while Big Lots reported a sharply wider loss than last year. The bottom line at both the retailers missed analysts' estimates. The U.S. Food and Drug Administration said it has granted approval for Ferring Pharmaceuticals Inc.'s fecal microbiota product Rebyota. The approval is for the prevention of recurrence of Clostridioides difficile infection or CDI in individuals 18 years of age and older. Rebyota will be used after an individual has completed antibiotic treatment for recurrent CDI. Salt Lake City, Utah-based Rocky Mountain Pies, LLC is recalling Red Button Vintage Creamery French Silk Pie citing possible presence of undeclared almonds, a known allergen, the U.S. Food and Drug Administration said. The recall involves 31.88 oz French Silk Pie with the lot code beginning with 2 266. Only UPC code 0 41172 81290 9 is involved in the recall.
Follow RTT